Jason Westin, MD, MS, FACP, MD Anderson Cancer Center

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

August 7th 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023

July 31st 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 24th 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

What is the Role of Bispecifics in Relapsed/Refractory DLBCL?

July 17th 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy

July 17th 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

July 10th 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel

July 3rd 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel

July 3rd 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL

June 26th 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

June 26th 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Overview of Relapsed/Refractory DLBCL and Management Strategies

June 19th 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

June 19th 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients

October 16th 2020

Dr. Westin on Treatment Challenges in Large Cell Lymphoma

March 24th 2020

Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.

Dr. Westin on the Role of R-CHOP in DLBCL

March 18th 2020

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Dr. Westin on Potential for Chemo-Free Treatment in Large Cell Lymphoma

March 13th 2020

Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.